Palatin (PTN) Technologies announced the U.S. FDA has granted “orphan drug” designation to PL7737, an oral treatment that activates the melanocortin-4 receptor, for leptin receptor deficiency, including obesity caused by this condition. IND submission is planned for 4Q25; Clinical data expected in 1H26.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTN:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue